Zevra Therapeutics, Inc. ZVRA Indefinite-Lived Research and Development Assets

Indefinite-Lived Research and Development Assets at other companies

HTF

Heartflow, Inc. Common StockHTFL

$15.41M-25.5%

PhotronicsPLAB

$3.9M+43.5%

KEE

Keel Infrastructure Corp. Common StockKEEL

$2.19M-50.8%

Tarsus Pharmaceuticals, Inc.TARS

$7.96M-63.4%

Lantheus HoldingsLNTH

$6.19M-79.2%

BlackSky TechnologyBKSY

$8.38M-29.4%

Other financials

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation

See full

Market cap$782.09M+58.2%

Enterprise value$687.64M+32.5%

P/E6.3×—

P/S6.4×-5.8×

Profitability

See full

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s indefinite-lived research and development assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s indefinite-lived research and development assets?: Zevra Therapeutics, Inc. (ZVRA) reported indefinite-lived research and development assets of $2M in Q1 2026.